Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OKUR vs ASMB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OKUR Captures Overall Composite Edge (36.0 SELL vs 30.4 SELL), While ASMB Leads 4–2 on Growth & Valuation Pillars

OKUR Overall Winner 6-Pillar Tally: OKUR 2 – 4 ASMB Matrix Metrics: OKUR 5 – 4 ASMB

As of Nov 20, 2026, OnKure Therapeutics, Inc. (OKUR) captures the overall head-to-head institutional edge over Assembly Biosciences, Inc (ASMB) on higher Unified Composite conviction (36.0/100 SELL vs. 30.4/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality, Options & Positioning), while ASMB wins 4–2 across the 6-pillar growth and valuation breakdown. OKUR trades at $2.70 (N/M Forward P/E, 0.0% operating margin) versus ASMB at $22.19 (N/M Forward P/E, -31.8% operating margin).

  • Growth vs. Quality Trade-Off: OKUR earns the overall head-to-head edge with a stronger Unified Composite Score (36.0/100 SELL vs. ASMB 30.4/100 SELL) and 0.96β · 100% Vol risk profile, whereas ASMB leads top-line expansion (-72.6% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although OKUR compares more favorably head-to-head, both OKUR (36.0/100 SELL) and ASMB (30.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile ASMB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OKUR vs ASMB
OKUR NASDAQ Head-to-Head Winner
OnKure Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$2.70
-2.17% 1D
Market Cap $113.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 100% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 20.0 Fund 46.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.6%) with fading momentum, RSI 49
RSI-14: 48.7 · SMA20: $2.76 · SMA50: $2.67
ASMB NASDAQ
Assembly Biosciences, Inc
Pharmaceutical Preparations
$22.19
-1.38% 1D
Market Cap $460.7M
TTM Revenue $67M
Forward P/E N/M
Beta / 30D Vol 0.92β · 57% Vol
Unified Composite Score
30.4 / 100 SELL
Tech 20.0 Fund 31.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.5 · SMA20: $20.95 · SMA50: $22.17

6-Pillar Scorecard Institutional Category Breakdown (OKUR 2 – 4 ASMB)

Columns: Metric · OKUR · ASMB
1. Valuation Multiples ASMB
Forward P/E N/M N/M
Trailing P/E N/M 30.0x
PEG Ratio N/M N/M
EV / Revenue N/M 6.9x
2. Growth & Scale ASMB
Revenue Growth (YoY) +0.0% -72.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $67M
Market Cap $113.7M $460.7M
3. Profitability & Quality OKUR
Gross Margin N/A -0.4%
Operating Margin 0.0% -31.8%
Net Profit Margin 0.0% -16.6%
Return on Equity (ROE) -55.2% -4.6%
4. Balance Sheet & Cash Flow ASMB
Cash Generation (TTM) -$48M -$21M EBITDA
Cash Flow Margin N/A -31.7% EBITDA Mgn
Net Cash / Leverage $151M Net Cash $14.67 Book/Sh · -4.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OKUR
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 89.1% (100th %ile) 109.3% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ASMB
OpEx & R&D Intensity N/A 31.4% of Rev ($21M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OKUR (5) vs ASMB (4)
Institutional Metric OKUR ASMB Criterion Row Edge
Market Capitalization
Scale
$113.7M $460.7M Larger Scale ASMB
Trailing P/E Ratio
Valuation
N/M 30.0x Lower Multiple ASMB
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -72.6% Higher Growth OKUR
Operating Margin (TTM)
Profitability
0.0% -31.8% Higher Margin OKUR
Net Profit Margin
Profitability
0.0% -16.6% Higher Margin OKUR
Return on Equity (ROE)
Capital Efficiency
-55.2% -4.6% Higher ROE ASMB
52-Week Range Position
Momentum
20% ($2–$5) 15% ($19–$40) Stronger Trend OKUR
Beta / 30D Volatility
Risk Regime
0.96β · 100% Vol 0.92β · 57% Vol Lower Realized Risk ASMB
Unified Institutional Score
Composite Signal
36.0 / 100 (SELL) 30.4 / 100 (SELL) Higher Composite OKUR
Trailing 12M Revenue (USD)
Operating Scale
N/A $67M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -0.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$48M ($151M Net Cash) -$21M EBITDA ($14.67 Book/Sh · -4.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ASMB +4.77 pp
OKUR: +4.65% · ASMB: +9.42%
3M Horizon OKUR +6.51 pp
OKUR: -30.59% · ASMB: -37.1%
6M Horizon ASMB +14.17 pp
OKUR: -35.87% · ASMB: -21.7%
1Y Horizon OKUR +39.44 pp
OKUR: -2.17% · ASMB: -41.61%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKUR vs ASMB. Trailing 12-month operating profitability (OKUR 0.0% vs ASMB -31.8%) and valuation multiples (OKUR N/M vs ASMB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OKUR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-55.2% · N/M
ASMB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$67M
Gross Margin-0.4%
Op. Margin-31.8%
ROE / Fwd P/E-4.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OKUR SURGE
8d in phase · OBV DISTRIBUTION
Current IV 89.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact OKUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ASMB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 109.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ASMB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OKUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $113.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ASMB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $460.7M market capitalization and -31.8% operating margin.
OpEx & R&D Reinvestment 31.4% of Rev ($21M)
90D Engineering Disclosures 0 Published

Investor FAQ OKUR vs ASMB Key Questions & Quantitative Answers

As of Nov 20, 2026, OnKure Therapeutics, Inc. (OKUR) captures the overall head-to-head institutional edge over Assembly Biosciences, Inc (ASMB) on higher Unified Composite conviction (36.0/100 SELL vs. 30.4/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality, Options & Positioning), while ASMB wins 4–2 across the 6-pillar growth and valuation breakdown. OKUR trades at $2.70 (N/M Forward P/E, 0.0% operating margin) versus ASMB at $22.19 (N/M Forward P/E, -31.8% operating margin). Growth vs. Quality Trade-Off: OKUR earns the overall head-to-head edge with a stronger Unified Composite Score (36.0/100 SELL vs. ASMB 30.4/100 SELL) and 0.96β · 100% Vol risk profile, whereas ASMB leads top-line expansion (-72.6% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although OKUR compares more favorably head-to-head, both OKUR (36.0/100 SELL) and ASMB (30.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile ASMB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ASMB leads the Growth & Scale pillar: OKUR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ASMB at -72.6% YoY revenue growth and +0.0% YoY earnings growth on $67M TTM revenue (-0.4% gross margin, -31.8% operating margin). On trailing 12-month operating scale, OKUR generates N/A in USD-normalized revenue versus $67M for ASMB. In operating R&D and SG&A reinvestment, OKUR deploys N/A (0 90-day corporate R&D disclosures) versus 31.4% of Rev ($21M) (0 disclosures) for ASMB.

ASMB screens cheaper on headline valuation multiples. OKUR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ASMB trades at N/M Forward P/E, 30.0x Trailing P/E, N/M PEG, and 6.9x EV/Revenue (-31.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKUR (-55.2% ROE) versus ASMB (-4.6% ROE) capital efficiency.

In options market volatility and institutional positioning, OKUR carries 89.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.96β · 100% Vol realized risk). By comparison, ASMB carries 109.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 57% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.